Back to results
US 9,309,310 B2Granted
Nucleic acids encoding anti-C5a antibodies
AssigneeAlexion Pharmaceuticals, Inc.
InventorsRussell P. Rother, Douglas L. Sheridan, Paul P. Tamburini, Yuchun Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospholipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Claims20
An isolated nucleic acid comprising a nucleotide sequence encoding an antibody, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises:
- (a) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:140;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:96;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:142;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:144;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
- (b) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21;
- and a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:67;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30;
- (c) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:156;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:157;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:158;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:160;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:161;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:162;
- (d) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:164;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:165;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:166;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:168;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:169;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:170;
- (e) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:172;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:173;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:174;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:176;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:177;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:178;
- (f) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:84;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:85;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:86;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:116;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
- (g) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:88;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:89;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:90;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:120;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:121;
- (h) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:99;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:100;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:101;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:119;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:126;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:127;
- (i) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:113;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47;
- (j) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:110;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:111;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:136;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:137;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:138;
- (k) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:105;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:106;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:107;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:115;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:124;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:117;
- (l) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30;
- (m) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:29;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:30;
- (n) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:21;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47;
- or
- (o) a light chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:20;
- a light chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:38;
- a light chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:22;
- a heavy chain CDR1 comprising the amino acid sequence depicted in SEQ ID NO:28;
- a heavy chain CDR2 comprising the amino acid sequence depicted in SEQ ID NO:46;
- and a heavy chain CDR3 comprising the amino acid sequence depicted in SEQ ID NO:47.
88 more elements
An isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide, wherein the polypeptide comprises the amino acid sequence depicted in SEQ ID NO:
- 17, SEQ ID NO:
- 25, SEQ ID NO:
- 33, SEQ ID NO:
- 36, SEQ ID NO:
- 40, SEQ ID NO:
- 44, or SEQ ID NO:
- 49.
4 more elements
An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region is at least 90% identical to the amino acid sequence depicted in SEQ ID NO:
- 19, SEQ ID NO:
- 27, SEQ ID NO:
- 37, SEQ ID NO:
- 42, or SEQ ID NO:
- 45.
2 more elements
An isolated nucleic acid comprising a nucleotide sequence encoding an antibody variable region, wherein the antibody variable region comprises the amino acid sequence depicted in SEQ ID NO:
- 19, SEQ ID NO:
- 27, SEQ ID NO:
- 37, SEQ ID NO:
- 42, or SEQ ID NO:
- 45.
2 more elements
An isolated nucleic acid comprising a nucleotide sequence encoding an antibody, or antigen binding fragment thereof, wherein the antibody, or antigen binding fragment thereof, comprises a light chain variable region comprising the amino acid sequence depicted in SEQ ID NO:42 and a heavy chain variable region comprising the amino acid sequence depicted in SEQ ID NO:45.
Dependencies are inferred from the claim text.